RaNA is dedicated to advancing the treatment paradigm by spearheading the discovery of revolutionary RNA-targeted medicines that selectively activate gene expression within cells in the body. Our approach has broad therapeutic potential, opening up a vast number of hard-to-treat disease targets with significant need.
RaNA takes a multi-dimensional approach to developing RNA-based medicines. Using our deep expertise in genetics, RNA biology and biochemistry, and cellular and molecular biology, we assess disease indications from every angle and select the approach within our diverse platform best suited to selectively target and treat their underlying causes at the genetic (DNA), RNA or protein level.
Transcription is the first step of gene expression when DNA is copied into messenger RNA (mRNA). During this process, RaNA uses oligonucleotides, or small, highly selective molecules, designed to block long non-coding RNA (lncRNA) from recruiting complexes known as chromatin modifiers, which can suppress the expression of certain genes.
What’s so important about IncRNA?
By blocking the interaction between lncRNA and chromatin modifiers, transcription is activated, resulting in gene upregulation or expression. The result? The production of proteins is increased, in turn treating or preventing disease.
During post-transcription – after DNA is copied into mRNA but before translation – mRNA decay occurs naturally within our cells. Half-lives of mRNA limit the amount of therapeutic protein available in our bodies.
In patients with certain diseases, this presents an opportunity. RaNA’s oligonucleotides are designed to stabilize the structure of mRNA, increasing its half-life, thus increasing protein levels, which are important in treating and preventing disease.
Proteins play a vital role in our health. Many diseases are caused by the over- or under-production of critical proteins.
RaNA’s team of scientists has designed optimized messenger RNAs (mRNAs) which take advantage of the body’s endogenous protein expression machinery to produce intracellular, membrane-associated or secreted proteins. In other words, our technology enables a patient’s own cells to produce the proteins needed to treat or prevent diseases that cannot be addressed with current technologies.